-
Product Insights
AcelRx Pharmaceuticals Inc Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our AcelRx Pharmaceuticals Inc Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. AcelRx Pharmaceuticals Inc (AcelRx), is a specialty pharmaceutical company that develops and commercializes drugs for the treatment of pain. The company’s lead product candidate, Dsuvia (known as Dzuveo in Europe), is a single sufentanil sublingual tablet for treating of moderate-to-severe acute pain. Its pipeline also includes Zalviso (for US market), a drug and device combination product for the management...
-
Product Insights
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
IRAK-4 Pipeline Products Market Report Overview Interleukin-1 receptor-associated kinase 4 (IRAK-4) is a protein kinase involved in signaling innate immune responses from Toll-like receptors. Mutations in IRAK-4 result in IRAK4 deficiency and recurrent invasive pneumococcal disease. It phosphorylates E3 ubiquitin ligases Pellino proteins to promote pellino-mediated polyubiquitination of IRAK1. The ubiquitin-binding domain of IKBKG/NEMO binds to polyubiquitinated IRAK1 bringing together the IRAK1-MAP3K7/TAK1-TRAF6 complex and the NEMO-IKKA-IKKB complex. MAP3K7/TAK1 activates IKKs leading to NF-kappa-B nuclear translocation and activation. The IRAK-4 pipeline...
-
Product Insights
Hepatitis B Virus DNA Polymerase (Hepatitis B Virus Reverse Transcriptase or Hepatitis B Virus Ribonuclease H or EC 2.7.7.7 or EC 2.7.7.49 or EC 3.1.26.4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players
Hepatitis B Virus DNA Polymerase (Hepatitis B Virus Reverse Transcriptase or Hepatitis B Virus Ribonuclease H or EC 2.7.7.7 or EC 2.7.7.49 or EC 3.1.26.4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Hepatitis B Virus DNA Polymerase (Hepatitis B Virus Reverse Transcriptase or Hepatitis B Virus Ribonuclease H or EC 2.7.7.7 or EC 2.7.7.49 or EC 3.1.26.4) targeted pipeline therapeutics. The report provides comprehensive information...
-
Product Insights
Geranylgeranyl Pyrophosphate Synthase (Geranylgeranyl Diphosphate Synthase or Dimethylallyltranstransferase or Farnesyl Diphosphate Synthase or Farnesyltranstransferase or Geranyltranstransferase or GGPS1 or EC 2.5.1.29 or EC 2.5.1.1 or EC 2.5.1.10) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players
Geranylgeranyl Pyrophosphate Synthase (Geranylgeranyl Diphosphate Synthase or Dimethylallyltranstransferase or Farnesyl Diphosphate Synthase or Farnesyltranstransferase or Geranyltranstransferase or GGPS1 or EC 2.5.1.29 or EC 2.5.1.1 or EC 2.5.1.10) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Geranylgeranyl Pyrophosphate Synthase (Geranylgeranyl Diphosphate Synthase or Dimethylallyltranstransferase or Farnesyl Diphosphate Synthase or Farnesyltranstransferase or Geranyltranstransferase or GGPS1 or EC 2.5.1.29 or EC 2.5.1.1 or EC 2.5.1.10) targeted pipeline therapeutics. The...
-
Product Insights
Trifunctional Purine Biosynthetic Protein Adenosine 3 (Phosphoribosylglycinamide Formyltransferase or Phosphoribosylamine Glycine Ligase or Phosphoribosylformylglycinamidine Cyclo Ligase or GART or EC 2.1.2.2 or EC 6.3.3.1 or EC 6.3.4.13) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players
Trifunctional Purine Biosynthetic Protein Adenosine 3 (Phosphoribosylglycinamide Formyltransferase or Phosphoribosylamine Glycine Ligase or Phosphoribosylformylglycinamidine Cyclo Ligase or GART or EC 2.1.2.2 or EC 6.3.3.1 or EC 6.3.4.13) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Trifunctional Purine Biosynthetic Protein Adenosine 3 (Phosphoribosylglycinamide Formyltransferase or Phosphoribosylamine Glycine Ligase or Phosphoribosylformylglycinamidine Cyclo Ligase or GART or EC 2.1.2.2 or EC 6.3.3.1 or EC 6.3.4.13) targeted pipeline therapeutics. The...
-
Product Insights
Phosphatidylinositol 3,4,5 Trisphosphate 3 Phosphatase And Dual Specificity Protein Phosphatase PTEN (Mutated In Multiple Advanced Cancers 1 or Phosphatase And Tensin Homolog or PTEN or EC 3.1.3.16 or EC 3.1.3.48 or EC 3.1.3.67) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players
Phosphatidylinositol 3,4,5 Trisphosphate 3 Phosphatase And Dual Specificity Protein Phosphatase PTEN (Mutated In Multiple Advanced Cancers 1 or Phosphatase And Tensin Homolog or PTEN or EC 3.1.3.16 or EC 3.1.3.48 or EC 3.1.3.67) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Phosphatidylinositol 3,4,5 Trisphosphate 3 Phosphatase And Dual Specificity Protein Phosphatase PTEN (Mutated In Multiple Advanced Cancers 1 or Phosphatase And Tensin Homolog or PTEN or...
-
Product Insights
Casein Kinase I Isoform Delta (Tau Protein Kinase CSNK1D or CKI Delta or CSNK1D or EC 2.7.11.1 or EC 2.7.11.26) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players
Casein Kinase I Isoform Delta (Tau Protein Kinase CSNK1D or CKI Delta or CSNK1D or EC 2.7.11.1 or EC 2.7.11.26) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Casein Kinase I Isoform Delta (Tau Protein Kinase CSNK1D or CKI Delta or CSNK1D or EC 2.7.11.1 or EC 2.7.11.26) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of...
-
Product Insights
Xanthine Dehydrogenase-Oxidase (Xanthine Dehydrogenase or Xanthine Oxidase or Xanthine Oxidoreductase or XDH or EC 1.17.1.4 or EC 1.17.3.2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players
Xanthine Dehydrogenase/Oxidase (Xanthine Dehydrogenase or Xanthine Oxidase or Xanthine Oxidoreductase or XDH or EC 1.17.1.4 or EC 1.17.3.2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Xanthine Dehydrogenase/Oxidase (Xanthine Dehydrogenase or Xanthine Oxidase or Xanthine Oxidoreductase or XDH or EC 1.17.1.4 or EC 1.17.3.2) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of...
-
Product Insights
Cytosolic Phospholipase A2 (Phospholipase A2 Group IVA or PLA2G4A or EC 3.1.1.4 or EC 3.1.1.5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players
Cytosolic Phospholipase A2 (Phospholipase A2 Group IVA or PLA2G4A or EC 3.1.1.4 or EC 3.1.1.5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Cytosolic Phospholipase A2 (Phospholipase A2 Group IVA or PLA2G4A or EC 3.1.1.4 or EC 3.1.1.5) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The...
-
Product Insights
Angiotensin Converting Enzyme (Dipeptidyl Carboxypeptidase I or Kininase II or CD143 or ACE or EC 3.4.15.1 or EC 3.2.1.) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players
Angiotensin Converting Enzyme (Dipeptidyl Carboxypeptidase I or Kininase II or CD143 or ACE or EC 3.4.15.1 or EC 3.2.1.) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Angiotensin Converting Enzyme (Dipeptidyl Carboxypeptidase I or Kininase II or CD143 or ACE or EC 3.4.15.1 or EC 3.2.1.) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA),...